clinical trial · NCT07219420
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
UCB Biopharma SRL·phase3·recruiting·n = 320
Palmoplantar PustulosisBimekizumabPlacebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
started
Nov 14, 2025
primary completion
Dec 27, 2027
completion
Nov 22, 2029
last updated
Aug 27, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study With Open-Label Extension to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol